Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2021 Results Conference Call April 29, 2021 8:00 AM ET

Company Participants

Holly Manning - Senior Director of Investor Relations
Jacqualyn Fouse - Chief Executive Officer
Christopher Bowden - Chief Medical Officer
Darrin Miles - Chief Commercial Officer
Jonathan Biller - Chief Financial Officer and Head of Legal and Corporate Affairs
Bruce Car - Chief Scientific Officer

Conference Call Participants

Alethia Young - Cantor Fitzgerald & Co
Mohit Bansal - Citigroup Inc.
Peter Lawson - Barclays Bank PLC
Tessa Romero - JPMorgan Chase & Co
Mark Breidenbach - Oppenheimer & Co. Inc.
Kelsey Goodwin - Guggenheim Securities, LLC

Operator

Good morning, and welcome to Agios' First Quarter 2021 Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Holly Manning, Senior Director of Investor Relations.

Holly Manning

Thank you, operator. Good morning, everyone, and welcome to Agios' First Quarter 2021 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com.

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Daren Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Dr. Bruce Carr, our Chief Scientific Officer, will join for Q&A.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include Forward-Looking Statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those